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Abstract 
Introduction: Commonly used iron salt, ferrous sulphate for the treatment of iron deficiency anemia, has several 
gastrointestinal side effects. Nowadays new iron salts such as ferrous bisglycinate are marketed with claims of 
raising hemoglobin faster with fewer gastrointestinal side effects.  
Objective: To compare the efficacy of ferrous sulphate with ferrous bisglycinate for the treatment of iron 
deficiency anemia in children. 
Methods: This randomized controlled trial was carried out at Children Hospital, PIMS, Islamabad from July 2015 
to June 2016. A total of 136 children were selected through systematic sampling and randomized into 2 groups 
using a computer-generated table of random numbers; ferrous sulphate as group 1 and ferrous bisglycinate as 
group 2. Clinical outcome was assessed based on a mean increase in hemoglobin after 12 weeks of therapy in both 
groups. The data was entered and analyzed using SPSS version 20.    
Results: The baseline characteristics i.e. mean age, mean hemoglobin levels were similar in both study groups. 
After 12 weeks of treatment, the mean increase in hemoglobin was 1.8  ±1.59 g/dl in the ferrous sulphate group as 
compare to 2.5  ±1.31g/dl in ferrous bisglycinate group showing the higher level of rising with ferrous 
bisglycinate than ferrous sulphate, P =0.0033. 
Conclusion: Newer iron preparation, ferrous bisglycinate is a better treatment option than conventional 
preparation of ferrous sulphate for increasing hemoglobin in iron deficiency anemia in children.  
Keywords: Hemoglobin, iron, ferrous sulphate, ferrous bisglycinate, iron deficiency, anemia. 
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Introduction 
 
Anemia is defined as “a hemoglobin level of less than 
the 5th percentile for age”.1,2 About 30% of the world’s 
population is suffering from iron deficiency anemia 
(IDA) mostly residing in developing countries.3 In 
Pakistan, 65% of the general population including 
children and adults, is having IDA.4  WHO statistics 
shows that in the world 43% & in Pakistan 29% of 
children are suffering from iron deficiency.4 
Children less than 2 years of age have the highest risk 
due to the increasing demand for rapid growth.5,6 
Other causes of IDA are premature births, early 
clamping of the umbilical cord, prolonged exclusive 
breastfeeding greater than 6 months without iron 
supplementation, delayed weaning, excessive intake of 
cow milk, low iron absorption, chronic blood loss, and 
parasite infestation.3,7,8,9,10 
The most common sign of anemia is pallor which does 
not appear until hemoglobin (Hb) falls to 7-8 g/dl. So 
IDA is commonly missed by parents in early stages. 
Other than anemia, iron deficiency also causes fatigue, 
poor concentration, and memory resulting in poor 
school performance.11,12,6 It also leads to pica and 
pagophagia (desire to ingest rice).3,13 There is a 
positive association of iron deficiency with febrile 
seizures, breath-holding spells, irritability, nausea and 
reduced immunity.3,14,13,6               
To prevent IDA, WHO recommends daily doses of 30 
mg of iron and 250 µg of folic acid for 3 months.9,15 
Two commonly used iron preparations in children are 
ferrous sulphate and iron polymaltose complex. 
Ferrous sulphate raises Hb faster than iron 
polymaltose complex but has more side effects and 
less tolerability as compared to iron polymaltose 
complex.7,16,5 The side effects of ferrous sulphate 
include nausea, vomiting, abdominal pain, 
constipation, diarrhea and staining of teeth.16   
So we need such iron preparation which rapidly 
increases Hb level with good tolerability and fewer 
side effects. One such preparation is ferrous 
bisglycinate which is an amino acid chelate. It has 
higher bioavailability (90.9%) as compared to ferrous 
sulphate (26.7%).17,18 This is because it does not form 
insoluble compounds with iron absorption inhibitor 
found in high quantity in cereal-based diets like 
phytates, oxalates, and tannins.6 
Trials of ferrous bisglycinate versus ferrous sulphate in 
pregnant women showed that ferrous bisglycinate 
raises Hb faster and has high compliance due to fewer 
side effects.19   
One study in children showed that although Hb 
increases significantly in both ferrous sulphate and 
ferrous bisglycinate group plasma ferritin which 
represents iron stores in the body increases 
significantly only in ferrous bisglycinate group.17 
To date, no study has been conducted in Pakistan to 
compare the efficacy of ferrous sulphate with ferrous 
bisglycinate for the treatment of newly diagnosed IDA 
in children. Therefore, we are going to conduct this 
study to compare the efficacy of ferrous sulphate with 
ferrous bisglycinate for the treatment of iron 
deficiency anemia in children. 
 
Material & Methods 
 
After seeking permission from the Institutional Ethics 
Review Board of Pakistan Institute of Medical Sciences 
(PIMS), Islamabad, this randomized controlled trial 
was done at Children Hospital’s OPD of PIMS, from 
July 2015 to June 2016. Children of either gender with 
age ranging from 6 months to 60 months who were 
recently diagnosed as having IDA with serum Hb 
levels between 7 and 10.9 g/dl, MCV < 70, MCHC < 
20p g/dl; Serum ferritin <10 μg/L were included in 
the study. Children who have β thalassemia trait, 
chronic inflammatory diseases, renal insufficiency, 
active infections, or have been treated with drugs that 
interfered with iron absorption were excluded from 
our study.  
Total 136 children (68 in each group) were taken as 
sample size by using WHO sample size calculator with 
following values of calculations; Level of significance = 
5%, Power of test = 80%, Mean Hb P1 = 2.517+1.31, 
Mean Hb P2=1.817+1.59, Pooled SD = 1.45.  
A total of 136 children fulfilling the above-mentioned 
inclusion criteria were enrolled in the study by using 
systematic sampling.  A computer-generated table of 
random numbers was used to randomize the enrolled 
children into two study groups; ferrous sulphate as 
group 1 and ferrous bisglycinate as group 2. 
Demographic features such as age and gender were 
asked and noted on a specially designed proforma.  
Children randomized to group 1 were advised syrup 
ferrous sulphate with a daily dose of 5 mg of 
iron/kilogram of body weight in 2 divided doses for 
12 weeks.  Children randomized to group 2 were 
advised syrup ferrous bisglycinate with a daily dose of 
5 mg of iron/kilogram of body weight in 2 divided 
doses for 12 weeks.  
Afterward, all the children in both the study groups 
were sent home with the advice of a follow-up visit 
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after 4 weeks of starting iron therapy. On 4 week 
follow up visit, history regarding the compliance of the 
patient to iron supplementation and any of the 
associated side effects was asked from mothers/ 
caregivers and advised another follow-up visit after 12 
weeks of starting iron therapy. In this 2nd follow up 
visit, a blood sample was obtained from each enrolled 
child to examine the serum Hb levels. All the 
laboratory data was recorded on specially designed 
proforma and analyzed using SPSS version 20. For 
continuous variables such as age and Hb (at baseline, 
at 12 weeks and the increase in Hb) mean ± standard 
deviation was calculated. Frequencies and percentages 
were measured for categorical variables such as 
gender.  For comparison of the increase in Hb between 
the two study drugs, the Student t-test was used and 
p-values were obtained. P-value ≤0.05 was considered 
significant.  
 
Results 
 
In this study 136 children with IDA were enrolled, 68 
in each group. The mean age of children was 24±1.26 
months in the ferrous sulphate group while it was 
25±1.74 months in the ferrous bisglycinate group. In 
the ferrous sulphate group, 39 (57%) children were 
male and 29 (43%) children were female. Whereas in 
the ferrous bisglycinate group 40 (59%) children were 
male and 28 (41%) children were female.  
Baseline serum Hb and post-treatment serum Hb were 
analysed in both groups showing the more level of 
rising in ferrous bisglycinate group than ferrous 
sulphate group over the same period as shown in 
Table 1. 
Table 1: Comparison between Ferrous Sulphate and 
Ferrous Bisglycinate Groups 
Parameters Ferrous 
sulphate 
Mean+SD 
Ferrous 
bisglycinate 
Mean+SD 
 
p-
value 
Baseline Hb 
(g/dl) 
8.7±1.64 8.0±1.49 0.995 
Post 
Treatment 
Hb (g/dl) 
10.5±0.81 10.5±0.22 0.500 
Increase in 
Hb (g/dl) 
1.8±1.59 2.5±1.31 0.0033 
 
Discussion 
  
Iron deficiency is the most common micronutrient 
deficiency in the world.6 Our study shows that in the 
ferrous sulphate group means the age of children was 
24±1.26 months while it was 25±1.74 months in the 
ferrous bisglycinate group. In the ferrous sulphate 
group, 39 (57%) children were male and 29 (43%) 
children were female. Whereas in the ferrous 
bisglycinate group 40 (59%) children were male and 28 
(41%) children were female. Baseline serum Hb 
analysis shows that in the ferrous sulphate group 
means Hb level was 8.7 ±1.64 while in ferrous 
bisglycinate groups mean Hb level was 8.0 ±1.49. Post-
treatment serum Hb analysis shows that in the ferrous 
sulphate group means Hb level was 10.5 ±0.81 and in 
ferrous bisglycinate group mean Hb level was 10.5 
±0.22. It shows that Hb raises more with ferrous 
bisglycinate than ferrous sulphate over the same 
period. The findings of the current study are 
comparable to other similar studies. 
 In a study conducted by Duque et al on school 
children of Mexico City, 200 children with decreased 
ferritin levels were compared and randomly assigned 
to two groups. One group was given ferrous sulphate 
and the other was given ferrous bisglycinate at a dose 
of 30 mg /day for 12 weeks. Serum ferritin 
concentration was almost the same in both groups 
after 1 week of completing iron supplementation but 
after 6 months of completing iron supplementation; it 
was significantly higher in ferrous bisglycinate group 
as compared to ferrous sulphate group.6 
In another study by Ribeiro and Sigulem showed that 
ferrous bisglycinate cause a significant increase in Hb 
in children when given at the dose of 5mg/kg/day. In 
that study, the effect on serum ferritin concentration 
was not checked.20  
Rojas and her colleague did their study on preschool 
children by giving milk fortified with ferrous sulphate 
to one group and milk fortified with ferrous 
bisglycinate to other groups. After 2 months they 
found a significant increase in serum ferritin in the 
ferrous bisglycinate group as compared to the ferrous 
sulphate group (p=0.022). Hb, hematocrit and adverse 
reactions were the same in both groups.21  
A study by Pineda et al. showed that although Hb 
increases significantly in both ferrous sulphate and 
ferrous bisglycinate group serum ferritin increases 
significantly only in iron bisglycinate group after 28 
days of iron supplementation at the rate of 
5mg/kg/day (P < 0.005).17  
Bovell-Benjamin et al studied college students who 
were given ferrous sulphate and ferrous bis-glycinate 
mixed with maize porridge in a breakfast meal. The 
iron from the ferrous bisglycinate was absorbed 4 
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times more than that from the ferrous sulfate (p < 
0.05).18  
Iost et al. also reported that low Hb concentrations in 
young children can be increased through daily 
consumption of fluid milk fortified with 3 mg of 
ferrous bisglycinate.22  
Various studies show that ferrous bisglycinate has 
lesser gastrointestinal side effects than ferrous 
sulphate. Coplin et al reported that ferrous 
bisglycinate has better tolerability as compared to 
ferrous sulphate.23   
Although the current study shows that ferrous 
bisglycinate is better in terms of improvement in Hb 
level. However, this study has a few limitations. 
Serum ferritin levels which are more significant tests 
for the evaluation of IDA could not be performed after 
completion of therapy. The study would have become 
more powerful if the tolerability of both forms of iron 
was assessed and compared.  
It is suggested that further studies should be done on 
related research areas so that the efficacy and 
tolerability of newer iron preparations are further 
evaluated.    
 
Conclusion 
  
Newer iron preparation, ferrous bisglycinate is a better 
treatment option than conventional preparations of 
ferrous sulphate for increasing Hb in IDA in children. 
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